Overview of Group B Streptococcus
Invasive Group B Streptococcal disease emerged in the 1970's as the leading
cause of infectious disease in infants. Infants with early onset infection (<7 days
of age) may show symptoms of respiratory distress, apnea or sepsis. Early-onset
GBS disease is most commonly associated with sepsis and pneumonia, however it may
lead to meningitis.
The fatality rate for infants with early-onset GBS disease is currently estimated
at 4%-6%. Surviving infants may experience long-term disabilities including hearing
loss, vision loss, or mental retardation. The primary risk factor for early-onset
GBS disease is maternal colonization.
If detected, intrapartum transmission of Group B Streptococcus or early-onset
GBS disease can be prevented by administration of antibiotic prophylaxis prior to
delivery. Traditional culture has been the standard of care for most laboratories
in North America for many years, but the significant potential for false negatives
is creating a shift in testing.
Molecular Testing for Group B Streptococcus
Molecular testing is growing due to its ability to provide more accurate results
than traditional culture methods. illumigene® Group
B Streptococcus (GBS) exceeds the performance of current Group B Streptococcus
test methods. illumigene® GBS fully complies with the
CDC guidelines for antepartum testing at 35 - 37 weeks gestation while
allowing the flexibility of testing with multiple broth-enriched specimen types
(Lim, TransVag, Carrot).
illumigene® GBS provides definitive answers and confident
results, putting the right information at the right time in the hands of physicians.
Reliable results make it possible for mothers to be treated at the time of delivery,
ensuring the best outcome for baby.